Kn026 is a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2), binding to HER2 domains II and IV. It demonstrates a well-tolerated safety profile and promising anti-tumor efficacy in advanced HER2-positive gastric cancer (GC) and gastroesophageal junction cancer (GEJC). MW: 145.19 KD.